A

Aravax

5 employees

Aravax is an early stage biotechnology company focused on developing the first safe and rapidly effective treatment for peanut allergy.

Basic info

Industry

biotechnology research

Sectors

Biotechnology
Health Care
Wellness

Date founded

2015

Funding rounds raised

Total raised

$20M

from 3 investors over 3 rounds

A

Aravax raised $20M on December 20, 2022

Investors: Brandon Capital and Tenmile

A

Aravax raised undisclosed on January 1, 2016

Investors: Brandon Capital Partners

FAQ